Inmune Bio (INMB) Net Income (2018 - 2026)
Inmune Bio (INMB) posted Net Income of -$6.1 million for Q1 2026, down 0.86% sequentially from -$6.0 million in Q4 2025, and up 68.51% YoY from -$3.6 million in Q1 2025.
Inmune Bio (INMB) Net Income (2018 - 2026) Analysis & Trends
Inmune Bio has reported Net Income for 9 years, with the latest figure at -$6.1 million in Q1 2026.
- Quarterly Net Income rose 68.51% year-over-year to -$6.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$45.4 million (up 78.11% YoY) and the FY2025 annual result came in at -$82.1 million, down 20.15% from the prior year.
- Net Income retreated to -$6.1 million in Q1 2026 per INMB's latest filing, from -$6.0 million in the prior quarter.
- Over five years, Net Income peaked at -$6.0 million in Q4 2025 and troughed at -$532.4 million in Q3 2022.
- A 5-year average of -$51.6 million and a median of -$9.3 million in 2023 frame the typical range for Net Income.
- The sharpest annual moves came in 2023 and 2024: Net Income soared 97.48% in 2023, then sank 1072.11% in 2024.
- Over 5 years, Net Income stood at -$6.5 million in 2022, then slumped by 42.53% to -$9.3 million in 2023, then declined by 13.31% to -$10.5 million in 2024, then jumped by 42.65% to -$6.0 million in 2025, then slipped by 0.86% to -$6.1 million in 2026.
- According to Business Quant data, Net Income over the past three periods registered -$6.1 million, -$6.0 million, and -$8.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Inmune Bio | 61.59 Mn | 43.18 Mn | - | -1.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.09 Mn |
| Mar 31, 2026 | -6.07 Mn |
| Dec 31, 2025 | -6.02 Mn |
| Sep 30, 2025 | -8.64 Mn |
| Jun 30, 2025 | -24.72 Mn |
| Mar 31, 2025 | -19.28 Mn |
| Dec 31, 2024 | -10.50 Mn |
| Sep 30, 2024 | -157.29 Mn |
| Jun 30, 2024 | -20.52 Mn |
| Mar 31, 2024 | -34.83 Mn |
| Dec 31, 2023 | -9.26 Mn |
| Sep 30, 2023 | -13.42 Mn |
| Jun 30, 2023 | -7.04 Mn |
| Mar 31, 2023 | -7.04 Mn |
| Dec 31, 2022 | -6.50 Mn |
| Sep 30, 2022 | -532.44 Mn |
| Jun 30, 2022 | -6.85 Mn |
| Mar 31, 2022 | -6.91 Mn |
| Dec 31, 2021 | -9.47 Mn |
| Sep 30, 2021 | -54.19 Mn |